In addition to effectively reducing 24-h plasma glucose levels, dorzagliatin improved the GSIS in patients with T2D who were treated for 28 days, as indicated by a significant increase in the early phase insulin secretion index (ΔC30/ΔG30) and homeostasis model assessment 2 of β-cell function (HOMA2-β) from baseline in a Phase 1 trial [33]. The gene discussed is INS; the disease is type 2 diabetes mellitus.